Re tissue retention was greatly prolonged, with only 10% of the injected dose being eliminated at 72h. Rat median survival was significantly improved for the group treated with 8Gy 188 Re-SSS LNC compared to the control group and blank LNC-treated animals. The increase in the median survival time was about 80% compared to the control group; 33% of the animals were long-term survivors. The dose of 8Gy proved to be a very effective dose, between toxic (10-12Gy) and ineffective (3-4Gy) doses. Conclusions These findings show that CED of 188 Re-loaded LNC is a safe and potent anti-tumour system for treating malignant gliomas. Our data are the first to show the in vivo efficacy of 188 Re internal radiotherapy for the treatment of brain malignancy.
conclusive results have often been associated with the use of radiotherapy, alone or in combination with chemotherapy. Whereas classic radiotherapy involves external sources of radiation, internal tumour radiotherapy uses a radioisotope that is conjugated to a suitable agent such as an antibody, a peptide or a nanocarrier. Several nanoscale carriers (nanoparticles, liposomes, water-soluble polymers, micelles and dendrimers) have been developed for the targeted delivery of diagnostic and therapeutic cancer agents [3] . These carriers can selectively target cancer sites and carry large payloads, thereby improving cancer detection and therapy effectiveness. However, for therapeutic cancer applications, only a few attempts of internal radiotherapy have been described for the treatment of malignant gliomas [4, 5] . Among all the therapeutic radiopharmaceuticals used for radionuclide imaging and therapy, 188 Re is of widespread interest due to its attractive physical and chemical properties [6] linked to its short physical halflife of 16.9h with 155keV gamma emissions for imaging and its 2.12MeV beta emission for therapy [7] . Furthermore, the availability of 188 Re from a generator at a reasonable cost has increased the clinical applications of 188 Re-labelled radiopharmaceuticals [8] .
In a previous study, the formulation and biodistribution of 188 Re-labelled lipid nanocapsules (LNC) were assessed [9] . Neutral lipophilic complexes chosen for their affinity for hydrophobic substrates allowed the encapsulation of the radioelement in the LNC lipid core as well as labelling stability [10] . Prepared from a phase-inversion process [11] , these LNC are characterised by a stable monodispersal size distribution and a small diameter in the range of 20 to 100nm. The present work has focused on the therapeutic application of such 188 Re(S 3 CPh) 2 (S 2 CPh) complex ( 188 Re-SSS) LNC on a 9L rat glioma model. Convection-enhanced delivery (CED) [12] , a direct intra-cerebral drug delivery technique that uses a bulk flow mechanism to distribute molecules to clinically significant volumes of tissue, was used to administer 188 Re-SSS LNC into rat brains. The aim of this work was to test the capacity of different 188 Re dose-loaded nanocapsules to eradicate tumours by studying the prolonged survival time of 9L glioma-bearing rats in comparison with the injection of 188 Re perrhenate solution and blank LNC.
Materials and methods

Materials
Lipophilic Labrafac® CC (caprylic-capric acid triglycerides) was kindly provided by Gattefosse S.A. (Saint-Priest, France). Lipoïd® S75-3 (soybean lecithin at 69% of phosphatidylcholine) and Solutol® HS15 (a mixture of free polyethylene glycol 660 and polyethylene glycol 660 hydroxystearate) were a gift from Lipoïd Gmbh (Ludwigshafen, Germany) and BASF (Ludwigshafen, Germany), respectively. NaCl, dichloromethane and acetone were obtained from Prolabo (Fontenay-sous-bois, France). Deionised water was obtained from a Milli-Q plus system (Millipore, Paris, France).
Complex preparation
The lipophilic 188 Re-SSS [(bis(perthiobenzoato)(dithiobenzoato)rhenium(III)] was prepared according to a previously described process [9] . The radiochemical purity (RCP) of the 188 Re-SSS complex was checked by thin-layer chromatography as the ratio of migrated radioactivity to total radioactivity. Thin-layer chromatography was carried out using silica gel 60 F 254 alumina plates (Merck) and a solution of petroleum ether/dichloromethane (6/4, v/v) as an eluant (Rf 0.70). The detection was evaluated by a phospho-imager apparatus (Packard, Cyclone storage phosphor system).
Nanocapsule formulation
The preparation of 188 Re-SSS LNC was based on a phaseinversion process described by Heurtault et al. [11] . The suspension was prepared by mixing all the components under magnetic stirring (37.5mg Lipoid®, 423mg Solutol®, 514mg Labrafac®, 44.5mg NaCl and 1,481mg deionised water). Because of its precipitation in aqueous media, the 188 Re-SSS complex was first extracted with dichloromethane (1ml) and then added to the other components of the emulsion. The organic solvent was then removed by heating at 60°C for 15min. Three cycles of progressive heating and cooling between 85°C and 60°C were then carried out allowing the residual organic solvent to evaporate. At 70°C and during the last cycle, an irreversible shock was induced by dilution with cold deionised water (1ml at 2°C), leading to the formation of stable nanocapsules. Afterwards, slow magnetic stirring was applied to the suspension for 5min. Nanocapsule characterisation LNC were analysed for their size distribution using a Malvern Zetasizer® Nano Serie DTS 1060 (Malvern Instruments S.A., Worcestershire, UK). The complex formation yield was determined with a gamma counter (Packard Auto-Gamma 5,000 series) according to Eq. 1, and encapsulate rate was estimated according to Eq. 2. Before injection, 188 Re-SSS LNC were dialysed with deionised water at room temperature under magnetic stirring. Following this, dialysate samples were collected and counted to determine a dialysis recovery as shown in For intra-cranial implantation, 10μl of 10 3 9L cell suspension were injected into the rat striatum at a flow rate of 2μl/min using a 10-μl syringe (Hamilton® glass syringe 700 series RN) with a 32-G needle (Hamilton®). For that purpose, rats were immobilised in a stereotaxic head frame (Lab Standard Stereotaxic; Stoelting, Chicago, IL). A sagittal incision was made through the skin, and a burr hole was drilled into the skull with a twist drill. The cannula coordinates were 1mm posterior from the bregma, 3mm lateral from the sagittal suture and 5mm below the dura (with the incisor bar set at 0mm). The needle was left in place for an additional 5min to avoid expulsion of the suspension from the brain during removal of the syringe, which was withdrawn very slowly (0.5mm/min).
Convection-enhanced delivery procedure
On day6, 60μl of the LNC suspension was injected by CED at the coordinates of the tumour cells. Infusions were performed at the depth of 5mm from the brain surface using a 10-μl Hamilton® syringe with a 32-G needle. This syringe was connected to a 100-μl Hamilton 22-G syringe containing the product (Harvard Apparatus, Les Ulis, France) through a cannula (CoExTM PE/PVC tubing, Harvard Apparatus). CED was performed with an osmotic pump PHD 2,000 infusion (Harvard Apparatus) by controlling a 0.5 μl/min rate for 2h.
Sub-groups
The rats treated with 188 Re-SSS LNC were put into four random sub-groups and received rhenium activity equivalent to 1.1 (group 1: n = 5; 3Gy), 2.8 (group 2: n = 6; 8Gy), 3.7 (group 3: n = 4; 10Gy) and 4.4MBq (group 4: n = 4; 12Gy), respectively. Group 5 received 60μl of 188 Re perrhenate solution equivalent to 1.5MBq (n = 4; 4Gy). Group 6 received blank LNC (n = 7), and rats of group 7 (control group) did not receive treatment by CED on day6 but were anaesthetised with the same protocol compared to the rats who underwent a CED infusion (n = 8). After treatment, rats from groups 4 and 5 were maintained in metabolism cages for 72h and were fed ad libitum. Urine and faeces were collected every 12h and measured with a gamma counter (Packard Auto-Gamma 5,000 series) to evaluate 188 Re elimination. Doses delivered to tumours were estimated according to Eq. 5:
where A =
188
Re activity delivered to each rat, E βmoy = mean energy, T = physical half-life (16.9h) and d and V = density and volume of the irradiated organ. The irradiated organ was considered to be a sphere with a radius equivalent to 188 Re range of beta particles in tissue ( 188 Re R tissue = 10.15mm) [7] and with a density of 1.
MRI and
1 H-magnetic resonance spectroscopy MRI was performed with a Bruker Avance DRX 300 (Germany) apparatus equipped with a vertical superwide-bore magnet of 7T. Rapid qualitative T2-weighted images were obtained using rapid acquisition with relaxation enhancement (RARE) sequence (TR = 2,000ms; mean echo time (Tem) = 31.7ms; RARE factor = 8; FOV = 3 × 3cm; matrix 128 × 128; nine contiguous slices of 1mm, eight acquisitions). Magnetic resonance spectroscopy (MRS) was performed using a PRESS sequence with water suppression and cardiac triggering (Rapid Biomed GmbH, Germany).
1 H spectra were acquired with the following parameters: TR/ TE = 1,500/11ms; NEX = 128; vowel size 27μl (3 × 3 × 3mm).
Statistical analysis
The Kaplan-Meier method was used to plot animal survival. Statistical significance was calculated using the log-rank test (Mantel-Cox Test). StatView software version 5.0 (SAS Institute) was used for that purpose, and tests were considered as significant with p values of less than 0.05. The different treatment groups were compared in terms of survival time, increase in survival time (IST median %), maximal survival time and long-term survivors.
Results
Complex and nanocapsule characterisation
188 Re-SSS complexes were obtained with satisfactory RCP. Physico-chemical properties of the LNC are given in Table 1 . In the proportions described, blank LNC were obtained with a mean size of 55.7 ± 1.7nm with a good polydispersity index (PI < 0.1).
188 Re-SSS LNC were measured at 55.5 ± 11.5nm, but an increase in polydispersity index (PI = 0.20) was observed. Measurement of LNC mean particle size before and after CED infusion showed that there was no size modification (data not shown).
188 Re complex formation yield was around 78%. Encapsulation of the 188 Re complex into LNC was very efficient (96.7%). Radiolabelling occurred during LNC formulation with important yields (98.5%) after elimination of 188 Re perrhenate, which was not incorporated into the complex by dialysis.
188 Re-SSS LNC were obtained with a final labelling yield of 73.9%.
Internal radiotherapy study
Descriptive and statistical data from the radiotherapy study are summarised in Table 2 . Rats were considered as longterm survivors if they survived up to 100days after tumour implantation (four times the median survival of non-treated rats). As shown in Fig. 1 , all animals of the control group died due to tumour progression by day27, and median survival was only 25days. Rats of group 6, which received a CED infusion of blank LNC, died within 33days postimplantation, and the median survival was 26days. There was no significant difference between these two groups (p > 0.05). The experiments established that rat median survival was improved significantly for group 3, which was treated The increases in median survival time (IST median %) are calculated in comparison to the control group. Survival data were analysed using the logrank test (Mantel-Cox test), which was considered as significant when the p values were less than 0.05. Re-SSS LNC compared with group 6 (blank LNC) and the control group (no treatment; p = 0.0010 and p = 0.0003, respectively). Animals treated with 8Gy 188 Re-SSS LNC showed excellent survival, with two of six rats surviving beyond day100, a median survival of 45days and an increase in the median survival time (IST median ) of 80% compared to the control group. At the highest dose of 188 Re activity (12Gy; group 1), 50% of the treated rats died after treatment, and median survival was only 27.5days. In spite of the presence of one long-term survivor in this group, comparisons with group 6 or 7 were not significant (p = 0.32). At the equivalent dose of 10Gy, treatment with 188 Re-SSS LNC resulted in median survival of 28.5days with one long-term survivor and an IST median that relapsed to 14%. No significant difference was observed with the group treated with blank LNC (p = 0.2386), whereas a slight significant difference was noted for this group compared to the control group (p = 0.0294). Rats in group 4 treated with 3Gy
188 Re-SSS LNC died within 33days post-implantation; their median survival was 28.0days with an IST median of 12%. A significant difference was only observed with the control group (p = 0.0277), whereas the significance was not shown with rats treated with blank LNC infusion (p = 0.4858). Group 5 treated with 188 Re perrhenate solution gave no positive results in terms of survival time because the median survival time was about 23.5days, and no significant difference was observed with rats from the control group (p = 0.1575).
To assess 188 Re elimination, urine and faeces in two groups (groups 4 and 5) were collected and measured. CED infusion of 188 Re perrhenate solution revealed that more than 80% was eliminated in 12h and about 94% after 72h post-CED (Fig. 2a) . Rhenium brain half-disappearance time (brain T 1/2 ) was equivalent to 7h, and 188 Re perrhenate was mainly excreted by the kidneys as 99.4% of the total excreted radioactivity was recovered in urine (Fig. 2b) . On the contrary, only 10% of 188 Re encapsulated in LNC was detected in urine and faeces 72h post-CED infusion. Among the 10% eliminated, LNC was mainly excreted in urine (75.8%; Fig. 2c ).
Internal radiotherapy side effects
Two of the four rats infused with the highest dose of 188 Re-SSS LNC (12Gy) died on day7, which was 1day posttreatment. The two other rats showed clinical signs of toxicity including lethargy and a significant weight loss of 25% by day18 (Fig. 3) . None of the other animals that underwent CED of 10, 8 or 3Gy
188 Re-SSS LNC died post- 188 Re perrhenate solution. Tumour proliferation was evaluated by MRI images. In vivo MRI images were assessed at day16 (10days post-CED) on one rat of the control group versus one rat treated with 10Gy
188 Re-SSS LNC (Fig. 4) . T2-weighted images of the non-treated rat showed a hyper-intense signal on the right striatum caused by tumour tissue (Fig. 4a) . On the contrary, images taken on the rat treated by internal radiotherapy showed a hypo-intense signal probably due to the CED infusion of 188 Re-SSS LNC (Fig. 4b) . Late side effects were also followed by MRI and by 1 H-MRS (Fig. 5) . Images taken on day 83 revealed that the rat treated by internal radiotherapy presented a lesion localised in the right brain, mainly in the striatum but which also affected the ventricle (Fig. 5a ). This lesion was still present on days 100 and 140 (Fig. 5b-c) .
1 H-MRS performed on day 100 revealed that spectral data for N-acetylaspartate (NAA), creatine (Cr) and choline were different in the right and left striata. In fact, the striatum affected by the lesion was characterised by a decrease in NAA and Cr associated with the presence of lactate (Fig. 5d ).
Discussion
The development of an in-house 188 W/ 188 Re-generator has greatly increased the use of 188 Re for treating various diseases [13] . Many new radiopharmaceuticals labelled with 188 Re have been developed, and some of them are currently used in clinical trials. Among different carriers, LNC labelled with a lipophilic complex of 188 Re ( 188 Re-SSS) can be obtained with high yield and satisfactory RCP [9] . This study investigated the therapeutic potential of this carrier for the treatment of malignant brain tumours. Due to the presence of the blood-brain barrier (BBB), which restricts the delivery of systemically administered agents, in situ administration was carried out using a direct intracranial drug delivery technique, CED [14] . This technique, introduced in 1994 as a method to circumvent the BBB and enhance the distribution of therapeutic agents by local administration, represents a promising technique for brain tumour therapy [15] .
The incorporation of 188 Re complexes in LNC did not change the size of the particles. Only the polydispersity index was slightly enhanced (PI=0.208) which represents a higher degree of heterogeneity but remained still inferior to 0.3. This can be explained by the presence of the lipophilic SSS complexes, which were required for 188 Re insertion inside the LNC core.
188 Re-SSS LNC could be obtained with a very high labelling yield. This result was expected as the incorporation of lipophilic molecules during the LNC formulation process generally led to high encapsulation efficiency whatever the radionuclide used [16, 17] . These rates are above those obtained in liposome formulations in which the radionuclides are generally post-inserted [18, 19] . In addition, agents directly infused into the brain in a small volume cannot readily disperse from their infusion site [20] ; this is the reason why CED infusion was used to administer the nanocapsules. MacKay et al. studied the different parameters that can influence the distribution of liposomes in the brain [21] . Based upon these findings, the ideal nanoparticle for CED would be less than 100 nm in diameter, have a neutral or negative surface charge and would need a targeting ligand to adhere to a target cell. To minimise the dose fraction that could be scavenged by perivascular cells, mainly perivascular macrophages, nanoparticles should be shielded by polyethylene glycol (PEG) and infused at a high total lipid concentration. Our LNC, loaded with a 188 Re neutral complex, have a mean particle size of 55 nm, are mainly composed of lipids and are covered by a soft layer formed by PEG. They can be conjugated with the OX26 antibody, which binds them to transferrin receptors that are over-expressed both on brain Re perrhenate solution for internal radiotherapy cerebral endothelial cells and on glioma cells [22] . Furthermore, Garcion et al. showed that LNC were able to penetrate intracellular compartments of glioma cells by interacting with cholesterol-rich microdomains [23] . Such characteristics confer ideal properties to LNC to be administered by CED in the rat brain.
To obtain a therapeutic effect, the elimination of the radionuclides deposed by CED in the brain must be as slow as possible. 188 Re in solution was eliminated after 12 h in accordance with findings by Knapp et al. [13] with 70% of free perrhenate in urine excretions after 12 h following an IV injection.
188 Re-SSS LNC were found to be a sustained residency system, which constitutes a major advantage (1% of elimination after 12 h). Like Noble et al. who showed that the encapsulation of CPT-11 in liposome resulted in at least 196-fold prolongation of residence time in brain tissue compared to free CPT-11 [25] , we demonstrated that the lipophilic nature of LNC led to a long radionuclide brain retention time allowing improved tumour irradiation.
The internal radiotherapy study by CED administration of 188 Re-SSS LNC was carried out on a well-known 9L rat brain tumour model [26] . The inoculation of 9L cells usually results in 100% tumour take with untreated Fisher 344 rats with a median survival between 20 and 30 days after tumour inoculation [27] . In our study, neither the anaesthetic procedure nor the injection of blank LNC H-MRS spectra realised at day 100. Signal intensities of creatine (Cr), N-acetyl aspartate (NAA) and Lactate (Lac) were compared between affected striatum (i) and safe striatum (ii). iii represents the difference between the two spectra a b Fig. 4 T2-weighted axial magnetic resonance images of a non-treated rat (a) at day 16 after 9L inoculation compared with a long-term survivor rat which received 10 Gy significantly modified the growth or lethality of the 9L gliomas, since the median survival time was 25 and 26 days for the untreated and the blank LNC groups, respectively. This was confirmed by MRI images where a tumour lesion is visible in a non-treated rat on day 16. As shown by Vonarbourg et al., 9L tumour growth is exponential since the tumour lesion volume is between 17±10 and 167± 19 μl between days 14 and 24 [28] . The median survival of the group treated by a CED infusion of 188 Re perrhenate solution was in the same range as none of the rats survived beyond 26 days. The hydrophilic nature of this solution provoked a very rapid elimination from the brain, which made tumour eradication impossible. Similar results were found by Vavra et al. for the administration of 14 C-sucrose, a small water-soluble compound in RG-2 rat gliomas, after CED infusion with less than 3% of the administered dose still present after 1 h in either the tumour or in surrounding brain tissues [29] .
On the contrary, thanks to the high retention of LNC in rat brains, conclusive dose-dependent results were obtained with internal radiotherapy by 188 Re-SSS LNC. Toxicity was observed with the highest studied doses, especially for 12 Gy 188 Re-SSS LNC. In fact, 50% of the rats died 1 day post-treatment, and a significant weight loss was observed for the two rats left, combined with other signs of toxicity like lethargy, passivity and poor grooming. Despite the presence of a long-term survivor within this group, an internal irradiation dose of 12 Gy can be considered as a toxic dose. For the intermediate dose of 10 Gy, results were mitigated. A significant difference in median survival time was observed compared to the control group but not with the group that received blank LNC. The increase in the median survival time of 14% and the presence of one longterm survivor make this dosage midway between the effective and toxic doses. LNC with an equivalent dose of 8 Gy constituted the most efficient group treatment in terms of survival because a high increase in the median survival time of 80% was noted compared to the control group and because two rats from this group (33%) were long-term survivors. CED injection at this dosage seemed to be well tolerated since no side effects were observed except a very slight weight loss observed in the few days after treatment. For the smaller dose equivalent to 3 Gy, internal radiotherapy with 188 Re-SSS LNC had no effect on survival time. This dosage was considered to be ineffective.
A comparison between our technique and external beam radiotherapy (XRT) is difficult, since the schemes of irradiation for many studies are very varied and often associated with chemotherapy [30] [31] [32] . The main theoretical advantage of internal radionuclide therapy with 188 Re-SSS LNC is that radiation can be delivered selectively to subclinical tumours and metastases that are too small to be imaged and thereby cannot be treated by surgical excision or local XRT.
However, despite obvious benefits noted with internal radiotherapy, side effects in rats were observed in the latter phase of the study. Magnetic resonance images carried out on one long-term survivor treated with 10 Gy 188 Re-SSS LNC revealed lesions mainly contained in the right striatum, which was obviously not related to tumour tissue as it was still present on day 140 of the study. The histologic nature of the lesion was not identified but was linked to radiation injury. In fact, a decrease of the signal intensity for NAA and Cr with an increase of the lactate signal has often been described in cases of radiation injury [33, 34] . In an attempt to improve the therapeutic ratio, the delivery of 188 Re-SSS LNC in multiple fractions separated in time may improve efficacy by decreasing late effects on critical normal structures, while maintaining a high radiation dose distribution within tumour tissue. In terms of dosimetric evaluation, a more detailed study that may consider these parameters should be pursued. To mimic clinical practice and because multi-therapy might be a solution in the fight against gliomas, chemotherapy could be included since LNC can be loaded with radiosensitive anti-cancer drugs such as etoposide or paclitaxel [17, 23, 35] .
